ILMN:NSD-Illumina Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 130.12

Change

0.00 (0.00)%

Market Cap

USD 20.90B

Volume

1.60M

Analyst Target

USD 347.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 42.12B
ICLR ICON PLC

N/A

USD 23.70B
NTRA Natera Inc

N/A

USD 15.55B
EXAS EXACT Sciences Corporation

N/A

USD 12.56B
MEDP Medpace Holdings Inc

N/A

USD 10.28B
RDNT RadNet Inc

N/A

USD 5.13B
SHC Sotera Health Co

N/A

USD 4.75B
NEOG Neogen Corporation

N/A

USD 3.61B
GH Guardant Health Inc

N/A

USD 3.09B
TWST Twist Bioscience Corp

N/A

USD 2.72B

ETFs Containing ILMN

CURG:LSE VanEck Genomics and Healt.. 6.45 % 0.00 %

N/A

USD 7.23M
BIS ProShares UltraShort Nasd.. 5.67 % 0.95 %

N/A

USD 3.74M
CURE:XETRA VanEck Genomics and Healt.. 5.36 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.12 % 0.00 %

N/A

N/A
DDOC:XETRA Global X Telemedicine & D.. 4.06 % 0.00 %

N/A

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.06 % 0.00 %

N/A

USD 4.62M
EDOC:LSE Global X Telemedicine & D.. 4.01 % 0.00 %

N/A

USD 3.87M
EDOG:LSE Global X Telemedicine & D.. 4.01 % 0.00 %

N/A

USD 0.23M
EDOC Global X Telemedicine & D.. 3.92 % 0.00 %

N/A

USD 0.05B
XGEN:XETRA Xtrackers MSCI Genomic He.. 3.84 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 3.64 % 0.35 %

N/A

USD 0.45B
FBT:LSE First Trust Global Funds .. 3.58 % 0.00 %

N/A

USD 7.86M
FBTU:LSE First Trust Global Funds .. 3.58 % 0.00 %

N/A

USD 7.86M
CDNA:CA CI Bio-Revolution Index E.. 2.86 % 0.00 %

N/A

CAD 6.10M
2B70:F iShares NASDAQ US Biotech.. 2.07 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 2.07 % 0.00 %

N/A

USD 0.52B
IBBQ Invesco Nasdaq Biotechnol.. 2.02 % 0.00 %

N/A

USD 0.04B
DOCG:LSE L&G Healthcare Breakthrou.. 1.89 % 0.00 %

N/A

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.89 % 0.00 %

N/A

USD 0.07B
HTEC Robo Global® Healthcare .. 1.89 % 0.00 %

N/A

USD 0.06B
ROBO:AU ETFS ROBO Global Robotics.. 1.88 % 0.00 %

N/A

USD 0.23B
XMLH:XETRA L&G Healthcare Breakthrou.. 1.86 % 0.00 %

N/A

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.86 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.86 % 0.00 %

N/A

USD 0.07B
IROB:XETRA L&G ROBO Global Robotics .. 1.84 % 0.00 %

N/A

USD 0.91B
ROBO:SW L&G ROBO Global Robotics .. 1.84 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 1.73 % 0.00 %

N/A

N/A
2B78:XETRA iShares Healthcare Innova.. 1.67 % 0.00 %

N/A

USD 1.14B
2B78:F iShares Healthcare Innova.. 1.67 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 1.65 % 0.00 %

N/A

N/A
IJJ iShares S&P Mid-Cap 400 V.. 1.52 % 0.25 %

N/A

USD 7.75B
IVOV Vanguard S&P Mid-Cap 400 .. 1.52 % 0.20 %

N/A

USD 0.93B
BIB ProShares Ultra Nasdaq Bi.. 1.44 % 0.95 %

N/A

USD 0.09B
QQEQ:CA Invesco NASDAQ 100 Equal .. 1.23 % 0.00 %

N/A

CAD 0.01B
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.74 % 0.00 %

N/A

USD 2.23B
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.74 % 0.00 %

N/A

USD 1.99B
SPY4:SW SPDR® S&P 400 US Mid Cap.. 0.74 % 0.00 %

N/A

USD 2.23B
IJH iShares Core S&P Mid-Cap .. 0.74 % 0.07 %

N/A

USD 91.24B
IVOO Vanguard S&P Mid-Cap 400 .. 0.73 % 0.15 %

N/A

USD 2.25B
ZMID:CA BMO S&P US Mid Cap Index .. 0.70 % 0.00 %

N/A

N/A
ZMID-F:CA BMO S&P US Mid Cap Index .. 0.70 % 0.00 %

N/A

CAD 2.03M
ZMID-U:CA BMO S&P US Mid Cap Index .. 0.70 % 0.00 %

N/A

N/A
SPX4:LSE SPDR® S&P 400 US Mid Cap.. 0.62 % 0.00 %

N/A

N/A
MIDU Direxion Daily Mid Cap Bu.. 0.56 % 1.10 %

N/A

USD 0.08B
MVV ProShares Ultra MidCap400 0.53 % 0.95 %

N/A

USD 0.14B
UMDD ProShares UltraPro MidCap.. 0.36 % 0.95 %

N/A

USD 0.03B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 2.85B
ALFA 0.00 % 0.65 %

N/A

N/A
IBCE 0.00 % 0.10 %

N/A

N/A
IBDD 0.00 % 0.10 %

N/A

N/A
MDYV SPDR® S&P 400 Mid Cap Va.. 0.00 % 0.15 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
ROBT First Trust Nasdaq Artifi.. 0.00 % 0.65 %

N/A

USD 0.44B
ROBO Robo Global® Robotics an.. 0.00 % 0.00 %

N/A

USD 1.17B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
ROBO Robo Global® Robotics an.. 0.00 % 0.95 %

N/A

USD 1.17B
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

N/A

N/A
ROBE:LSE L&G ROBO Global Robotics .. 0.00 % 0.00 %

N/A

USD 0.74B
ROBG:LSE L&G ROBO Global Robotics .. 0.00 % 0.00 %

N/A

USD 0.74B
ROBO:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

USD 0.74B
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.00 % 0.00 %

N/A

N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

N/A

N/A
BBIG:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -53.27% 24% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.27% 24% F 14% F
Trailing 12 Months  
Capital Gain -52.61% 22% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.61% 22% F 14% F
Trailing 5 Years  
Capital Gain -78.61% 16% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.61% 16% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -15.45% N/A N/A 20% F
Dividend Return -15.45% N/A N/A 20% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.31% N/A N/A 56% F
Risk Adjusted Return -46.37% N/A N/A 18% F
Market Capitalization 20.90B 95% A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector